- Scheme Category:
- Equity Scheme >
- Sectoral/Thematic Funds
NAV: ₹ 17.39 ↑ 0.35%
[as on 20 October, 2025]
NAV chart with SMA (Simple moving average) overlay
SMA (Simple Moving Average)
Returns
Name | YTD | 1D | 1W | 1M | 3M | 1Y | 3Y | 5Y | 7Y | 10Y |
---|
HDFC Pharma and Healthcare Fund - Growth Option | 1.77% | 0.35% | 0.81% | -1.48% | -1.02% | 6.87% | - | - | - | - |
Portfolio
Asset allocation
Equity | Debt | Realestate | Commodities | Cash & Equivalents |
---|
99.01% |
0.00% (Arbitrage: 0.00%) |
0.00% |
0.00% |
0.99% |
Equity
Name | Sector | Weight % |
---|
Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | 10.47% |
Divis Laboratories Ltd. | Pharmaceuticals & Biotechnology | 7.76% |
Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | 6.93% |
Lupin Ltd. | Pharmaceuticals & Biotechnology | 6.84% |
Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | 5.94% |
Max Healthcare Institute Limited | Healthcare Services | 4.66% |
Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | 4.50% |
Cipla Ltd. | Pharmaceuticals & Biotechnology | 4.32% |
Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | 3.81% |
Krishna Institute Of Medical Sciences Limited | Healthcare Services | 3.64% |
Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | 3.58% |
Aster DM Healthcare Limited | Healthcare Services | 3.55% |
Anthem Biosciences Limited | Pharmaceuticals & Biotechnology | 3.26% |
Eris Lifesciences Ltd | Pharmaceuticals & Biotechnology | 3.19% |
Metropolis Healthcare Ltd. | Healthcare Services | 2.64% |
Vijaya Diagnostic Centre Limited | Healthcare Services | 2.45% |
Acutaas Chemicals Limited | Pharmaceuticals & Biotechnology | 2.31% |
Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | 2.12% |
Wockhardt Ltd. | Pharmaceuticals & Biotechnology | 2.07% |
Cohance Lifesciences Limited | Pharmaceuticals & Biotechnology | 1.99% |
Dr. Lal Path Labs Ltd | Healthcare Services | 1.94% |
Fortis Healthcare Limited | Healthcare Services | 1.89% |
Jubilant Pharmova Limited | Pharmaceuticals & Biotechnology | 1.81% |
Piramal Pharma Limited | Pharmaceuticals & Biotechnology | 1.79% |
Sai Life Sciences Limited | Pharmaceuticals & Biotechnology | 1.67% |
BAJAJ HEALTHCARE LIMITED | Pharmaceuticals & Biotechnology | 1.34% |
Pfizer Ltd. | Pharmaceuticals & Biotechnology | 1.29% |
Laxmi Dental Limited | Healthcare Equipment & Supplies | 1.11% |
Ajanta Pharma Limited | Pharmaceuticals & Biotechnology | 0.14% |
Portfolio data is as on date 30 September, 2025
NAV (Net asset value) history
HDFC Pharma and Healthcare Fund - Growth Option - 30 days NAV history
Date | NAV |
---|
20 October, 2025 | 17.39 |
17 October, 2025 | 17.33 |
16 October, 2025 | 17.269 |
15 October, 2025 | 17.181 |
14 October, 2025 | 17.135 |
13 October, 2025 | 17.25 |
10 October, 2025 | 17.245 |
9 October, 2025 | 17.076 |
8 October, 2025 | 16.999 |
7 October, 2025 | 17.075 |
6 October, 2025 | 17.033 |
3 October, 2025 | 16.907 |
1 October, 2025 | 16.945 |
30 September, 2025 | 16.761 |
29 September, 2025 | 16.768 |
26 September, 2025 | 16.745 |
25 September, 2025 | 17.134 |
24 September, 2025 | 17.267 |
23 September, 2025 | 17.348 |
22 September, 2025 | 17.401 |
19 September, 2025 | 17.651 |
18 September, 2025 | 17.493 |
17 September, 2025 | 17.371 |
16 September, 2025 | 17.435 |
15 September, 2025 | 17.374 |
12 September, 2025 | 17.443 |
11 September, 2025 | 17.404 |
10 September, 2025 | 17.369 |
9 September, 2025 | 17.332 |
8 September, 2025 | 17.236 |
FAQ (Frequently asked questions)
What is latest/current NAV/price of HDFC Pharma and Healthcare Fund - Growth Option?
The latest NAV of HDFC Pharma and Healthcare Fund - Growth Option is 17.39 as on 20 October, 2025.
What are YTD (year to date) returns of HDFC Pharma and Healthcare Fund - Growth Option?
The YTD (year to date) returns of HDFC Pharma and Healthcare Fund - Growth Option are 1.77% as on 20 October, 2025.
What are 1 year returns of HDFC Pharma and Healthcare Fund - Growth Option?
The 1 year returns of HDFC Pharma and Healthcare Fund - Growth Option are 6.87% as on 20 October, 2025.